ClinicalTrials.gg
CompletedNCT02423200Updated Apr 3, 2018Results posted

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

A Phase 2 interventional study of VX-745 in Alzheimer's Disease, sponsored by EIP Pharma Inc. Completed at 1 site in United States. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-04-03.

Sponsored by EIP Pharma Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,360th of 1,609
16 · median 73
Started
2015
with 71 others
Phase 2
360 of 1,940
50 open now
Registered
697th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,360th largest by enrollment of the 1,609 interventional ones that give a count, is one of 72 that started in 2015, is one of 360 in phase 2, and was the 697th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD. The study will also evaluate the safety and tolerability of VX-745 in these patients during 6 weeks of dosing, as well as the plasma and cerebrospinal fluid concentrations of VX-745 during dosing.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 60 - 85 (inclusive)
  • Willing and able to provide
  • Clinical presentation consistent with MCI due to AD or of mild AD

    • Gradual progressive decline in memory function over >6 months
    • Amnestic presentation on neuropsychological testing with rapid forgetting (% reduction 1.5 standard deviations below the mean)
    • Clinical Dementia Rating (CDR) Sum of Box (SOB) score ≥0.5
    • (MMSE) range: 20 to 30
  • Brain hypometabolism by 18F-2-fluoro-2-deoxyglucose (FDG)-PET
  • Participants may be taking medications for AD, provided that the dose of these medications has been stable for >3 months.

Exclusion criteria

Exclusion Criteria:

  • Evidence of neurodegenerative disease other than AD
  • Inability for any reason to undergo MRI scans (e.g. pacemaker, vascular stent or stent graft). Patients who require sedation for screening procedures such as MRI may receive a short-acting sedative.
  • Psychiatric disorder that would compromise ability to comply with study requirements
  • History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years
  • Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder or metabolic/endocrine disorders or other disease that would preclude treatment with p38 MAP kinase inhibitor and/or assessment of drug safety and efficacy
  • Recent (\<90 days) changes to AD medications prescribed for cognitive reasons or with the potential to impact cognition
  • Psychotropic drugs taken within 1 month. Anticoagulant drugs taken within 1 week.
  • Participation in a study of an drug less than 6 months or 5 half-lives of the investigational drug, whichever is longer, before enrollment in the study
  • Male subjects with female partner of who are unwilling or unable to adhere to requirements
  • Female subjects who have not reached menopause or have not had a hysterectomy or bilateral oophorectomy/salpingoophorectomy
  • Positive urine or serum pregnancy test or plans desires to become pregnant during the course of the trial
  • Donation of >500 mL of blood or blood products within 2 months
  • History of alcohol and/or illicit drug abuse within 6 months.
  • Infection with hepatitis A, B or C or .
  • Any factor deemed by the investigator to be likely to interfere with study conduction
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    VX-745 dose level 1

    Active Group 1: VX-745 dose level 1 twice daily

    Drug: VX-745

  • Experimental
    VX-745 dose level 2

    Active Group 1: VX-745 dose level 2 twice daily

    Drug: VX-745

Interventions

  • DrugVX-745

    Orally-active P38 MAP kinase alpha-selective inhibitor

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines

    Cytokines: Of nine cytokines assessed, only CSF IL-8 quantifiable at all time points. And so, only IL-8 levels are being reported herein. The analysis was exploratory and no statistical analysis was performed.

    Time frame: Baseline and Day 42 of dosing with VX-745

Secondary outcomes

  1. Severe or Serious Adverse Events

    Number of patients with severe or serious adverse events

    Time frame: At baseline and at each study visit during (days 1, 7, 14, 21, 28, 35 and 42) and after (day 51) dosing

  2. Maximal CSF VX-745 Concentration

    Ratio fo CSF to plasma drug concentration at time matched time points. Samples taken

    Time frame: All samples with quantifiable CSF drug levels were included (n=12). Eight were obtained 3-hours post-dose, either on Day 1 (n=4) or Day 42 (n=4). 3 samples were at 6-hours post-dose on Day 42; and one was at 6-hours post-dose on Day 1.

  3. Episodic Memory Function

    Total Recall in Hopkins Verbal Learning Test (HVLT). Range is 0-36, with increases in score indicating improvement in cognitive function.

    Time frame: Change from baseline to Day 42

07

Results

Posted Apr 3, 2018

Participant flow

Participant flow — Overall Study
MilestoneNeflamapimod (VX-745) Dose Level 1Neflamapimod (VX-745) Dose Level 2
Started81
Completed71
Not completed10

Outcome measures

PrimaryPercent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines

Cytokines: Of nine cytokines assessed, only CSF IL-8 quantifiable at all time points. And so, only IL-8 levels are being reported herein. The analysis was exploratory and no statistical analysis was performed.

Time frame:
Baseline and Day 42 of dosing with VX-745
Reported as:
Mean · percentage of baseline at Day 42
Percent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines
percentage of baseline at Day 42Overall Study Population
Percent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines137 ± 115
SecondarySevere or Serious Adverse Events

Number of patients with severe or serious adverse events

Time frame:
At baseline and at each study visit during (days 1, 7, 14, 21, 28, 35 and 42) and after (day 51) dosing
Reported as:
Count of participants · Participants
Severe or Serious Adverse Events
ParticipantsNeflamapimod (VX-745) Dose Level 1Neflamapimod (VX-745) Dose Level 2
Severe or Serious Adverse Events00
SecondaryMaximal CSF VX-745 Concentration

Ratio fo CSF to plasma drug concentration at time matched time points. Samples taken

Time frame:
All samples with quantifiable CSF drug levels were included (n=12). Eight were obtained 3-hours post-dose, either on Day 1 (n=4) or Day 42 (n=4). 3 samples were at 6-hours post-dose on Day 42; and one was at 6-hours post-dose on Day 1.
Reported as:
Mean · ratio of plasma drug concentration
Maximal CSF VX-745 Concentration
ratio of plasma drug concentrationOverall Study Population
Maximal CSF VX-745 Concentration0.062 ± 0.01
SecondaryEpisodic Memory Function

Total Recall in Hopkins Verbal Learning Test (HVLT). Range is 0-36, with increases in score indicating improvement in cognitive function.

Time frame:
Change from baseline to Day 42
Reported as:
Mean · points on HLVT Total Recall (range 0-36)
Episodic Memory Function
points on HLVT Total Recall (range 0-36)Overall Study Population
Episodic Memory Function3.5 ± 3.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall Study Population—0/9 (0%)9/9 (100%)
Most frequent other events
Most frequent other events
EventOverall Study Population
DizzinessNervous system disorders2/9
HeadacheNervous system disorders2/9
SomnolenceNervous system disorders2/9
Orthostatic hypotensionVascular disorders1/9
DiarrheaGastrointestinal disorders1/9
VomitingGastrointestinal disorders1/9
Hot flushVascular disorders1/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)VX-745 Dose Level 1VX-745 Dose Level 2Total
Median71 (66 to 74)68 (68 to 68)71 (66 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)VX-745 Dose Level 1VX-745 Dose Level 2Total
Female505
Male314
Region of Enrollment
Region of Enrollment(count of participants)VX-745 Dose Level 1VX-745 Dose Level 2Total
United States819
08

Study locations

1 site
  • Parexel International
    Glendale, California 91206, United States
09

References and documents

Publications

  • Tormahlen NM, Martorelli M, Kuhn A, Maier F, Guezguez J, Burnet M, Albrecht W, Laufer SA, Koch P. Design and Synthesis of Highly Selective Brain Penetrant p38alpha Mitogen-Activated Protein Kinase Inhibitors. J Med Chem. 2022 Jan 27;65(2):1225-1242. doi: 10.1021/acs.jmedchem.0c01773. Epub 2021 May 11. PubMed 33974419 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Sep 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2015
First posted
Apr 22, 2015
Start
Apr 2015
Primary completionActual
Sep 2016
CompletionActual
Nov 2016
Results first posted
Apr 3, 2018
Last update
Apr 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02423200
Lead sponsor
EIP Pharma Inc
Responsible party
Sponsor
First posted
Apr 22, 2015
Start date
Apr 2015
Primary completion
Sep 2016
Completion
Nov 2016
Results posted
Apr 3, 2018
Last update
Apr 3, 2018

Study contacts

Hakop Gevorkyan, MD
principal investigator · Parexel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VX-745

Start the discussion